Background: Cytokine secretion has unwanted consequences in malignant and in inflammatory disorders. The deacetylase SIRT6 has proinflammatory activity but the underlying mechanisms and its biological significance remain unclear. 
The relationship between inflammation and carcinogenesis has been known for many years (1) . Chronic inflammation is a risk factor for cancer development. In addition, even in those cancers that do not develop in inflamed tissues, an inflammatory component is usually observed and it is now known to be an essential part of the malignant microenvironment (2, 3) . Inflammation contributes to tumorigenesis and cancer progression by supplying growth factors that sustain cancer cell proliferation and/or survival, proangiogenic factors, extracellular matrix-modifying enzymes that promote invasion and metastasis, and signals that lead to epithelial-mesenchymal transition (EMT) 1 (2, 4, 5) . Moreover, increased circulating levels of pro-inflammatory cytokines are responsible for systemic manifestations of disease, such as cachexia, fever, and sweats (6) (7) (8) (9) . Among other forms of cancer, pancreatic ductal adenocarcinoma (PDAC) is well known for its propensity to secrete high levels of proinflammatory factors that contribute to its clinical aggressiveness and to its metastatic potential (10). The mechanisms controlling cyto/chemokine production by inflammatory and cancer cells are only partially understood. A more detailed understanding of the molecular pathways leading to cancer-associated inflammation may lead to new therapeutic strategies with a strong impact on patient quality of life. Previous studies showed that intracellular nicotinamide adenine dinucleotide (NAD + ) levels influence the capacity of inflammatory cells to secrete cytokines such as Tumor necrosis factor α (TNF), Interleukin 6 (IL6), IL-1β, Interferon gamma (IFN-γ), IL2 and IL8 (11) (12) (13) (14) (15) . In line with these findings, the NAD + -lowering agent FK866 [a nicotinamide phosphoribosyltransferase (Nampt) inhibitor] was shown to have anti-inflammatory activity in mouse models of experimental autoimmune encephalomyelitis, arthritis, polymicrobial sepsis, and heart ischemia (11) (12) (13) 15 (20, 21) , and poly-(ADPribose)-polymerases (PARPs) that contribute to inflammation by enhancing mitogen activated protein kinase (MAPK) signaling (16). In addition, the enzyme poly-(ADP-ribose)-glycohydrolase (PARG) can degrade poly-(ADP-ribose) (22) , making available the Ca 2+ -mobilizing second messenger ADPr. Recently, the involvement of a third type of NAD + -degrading enzymes, the sirtuins, in immune responses has also been suggested (23) . One of the sirtuin members, Sirtuin 6 (SIRT6), was shown to be involved in TNF, IFN-γ, and IL8 production by immune cells (11, 12, 15) . The mechanism whereby SIRT6 promotes the synthesis of these cytokines remains unclear, although, in the case of TNF, it was proposed that SIRT6 may regulate the efficiency by which Tnf mRNA is translated (11) . Initially identified as a mono-ADP-ribosyltransferase (24), SIRT6 was subsequently shown to also possess NAD + -dependent deacetylase activity, similar to other sirtuin members (25) . However, purified SIRT6 produces O-acetyl-ADPr (OAADPr), the product of sirtuin-mediated deacetylations, at a much slower pace as compared to other active sirtuins, raising the questions of whether SIRT6 deacetylase activity is actually relevant in biological contexts (26) . SIRT6 was shown to have a role in telomere stability, DNA repair, and metabolic homeostasis (25, (27) (28) (29) , and its deficiency was shown to predispose to genomic instability and premature aging in the mouse (27) . Interestingly, this phenotype was characterized, among other aspects, by a profound lymphopenia, which is consistent with a role for SIRT6 in immunity. In this study, we investigated SIRT6's role in PDAC cell capability to produce proinflammatory cytokines. In doing so, we identified a novel role for this sirtuin in NAD + -and Ca 2+ -dependent signaling and, consequently, in immune gene expression and cell migration. Our results support the use of SIRT6 as a target to modify cancer cell pro-inflammatory phenotype and migratory propensity. 6 Phoenix cells were plated in 4 ml medium in 6 cm dishes and allowed to adhere for 24 h. Thereafter, cells were transfected with 4 µg plasmid DNA using TransIT-293 (Mirus Bio, Madison, WI, USA) according to the manufacturer's instructions. Viral supernatants were harvested after 36, 48 and 60 h and used to infect BxPC-3 cells (5 x  10 5 ) in 10 cm dishes in the presence of 5 µg/ml protamine sulfate. Successfully infected cells were selected using 1.5 µg/ml puromycin. Immunoblotting -Nuclear proteins were extracted from 4 x 10 6 cells as described before (30) 5'-GTCTTACACTTGGCACATTCT TCC-3') was performed using GoTaq® qPCR Master Mix (Promega Italia S.r.l., Milan, Italy) according to the manufacturer's protocol. Gene expression was normalized to housekeeping gene expression (GAPDH or RPLP0). Comparisons in gene expression were calculated using the 2 -ΔΔCt method.
Determination of intracellular NAD
+ levelsBxPC-3 cells were plated at a density of 3 x 10 5 cells/well in 6-well plates and cultured in the presence or absence of 100 nM FK866, with or without 1 mM nicotinic acid (Na). Then, cells were harvested and lysed in 0.1 ml 0.6 M perchloric acid (PCA) at 4 °C. Cell extracts were centrifuged for 3 min at 16000 x g, the supernatants were collected and an aliquot was diluted 200-fold in 100 mM sodium phosphate buffer, pH 8.0, for determination of NAD + content, as described (32 + incubated with NAD + ase (Sigma-Aldrich S.r.l., Milano, Italy) and the enzyme was then removed by filtration. The incubation was subjected to an analytical phosphate HPLC analysis, performed on a C18, 150 x 4 mm, 5 µm column (Waters, Milano, Italy) using the same conditions (buffers, gradient and flow rate) as described previously (33) . Fractions were collected every min, and the radioactive fraction (eluting at the same time of standard ADPr), was collected, dried, resuspended in water and used as tracer in the determination of intracellular ADPr content. Determination of the intracellular ADPr content -pBP, SIRT6 WT, SIRT6 H133Y, pRS and sh2 SIRT6 BxPC-3 cells (1 x 10 7 ) were recovered and centrifuged for 5 min at 300 x g. Cell pellets were lysed in 0.2 ml of 5% trichloroacetic acid at 4°C. Cell extracts were centrifuged for 3 min at 16000 x g; the supernatants were collected and neutralized with diethyl ether extractions. [
14 C]ADPr (10000 cpm) was added to the extracts, and the intracellular ADPr content was determined as in (14) . Briefly, samples were injected into a first HPLC analysis, using a PL-SAX column (solvent A was 0.02 M NH 4 HCO 3 , pH 7.5 and solvent B was 0.5 M NH 4 HCO 3 , pH 7.5). Fractions were collected every min and the radioactive fraction (the ADPr elution time was 14.5 min) was dried, resuspended in 0.25 ml water and subjected to the analytical phosphate HPLC analysis described above (the ADPr elution time was 30 min).
siRNA Transfection -Transient transfection of BxPC-3 cells was performed using the HiPerFect Transfection Reagent (Qiagen S.r.l., Milan, Italy). The day of transfection, cells were trypsinized after reaching 60-80% confluency and seeded at a density of 2 × 10 5 cells/well in 12-well plates. The siRNA targeting human TRPM2 (Stealth TM Select RNA i Oligo ID: HSS110995, Life Technologies, Carlsbad, CA, USA), SIRT1, GATA4 (both siGENOME SMARTpool, Dharmacon Inc., IL, USA) or the negative control siRNA (scr) (Stealth TM Negative Control) were diluted (100 nM) in 100 µl Opti-MEM® I Reduced Serum Media (Life Technologies) and incubated for 10 min at RT with 6 µl of HiPerFect transfection reagent. The transfection mixture was added drop-wise onto the cells to a final concentration of 10 nM siRNA/well. 24 h after transfection, cells were serum-starved O.N. and then stimulated for 1 h with 25 ng/ml PMA. Afterwards, cells were collected and RNA was isolated for qPCR analysis of IL8 and TNF as described before. Chemotaxis -pBP, SIRT6 WT, SIRT6 H133Y, pRS and sh2 SIRT6 BxPC-3 cells were resuspended at a density of 6 x 10 5 cells / ml in chemotaxis buffer (RPMI1640 medium containing 1% albumin). Chemotaxis assays were performed using 96-well ChemoTx system microplates (Neuro Probe, Inc, Gaithersburg, MD, USA) with a fibronectin-coated 8-µm pore size polycarbonate filter. PMA (100 ng/ml, final concentration) and IL8 (10 ng/ml, final concentration) were diluted in chemotaxis buffer and added in the bottom wells. Cell suspensions (25 µl) were placed directly on top of the filter and the plates were incubated for 4 h at 37 °C. The transmigrated cells were collected following ChemoTx system instructions, transferred into a 96-well plate and quantified by adding 60 µl of a solution composed of 0.2% NP40 and 1 µM SYTOX Green. After 20 min incubation at 37 °C, fluorescence was recorded (excitation, 485 nm; emission, 520 nm) with a fluorescence plate reader (Fluostar Optima, BMG Labtechnologies GmbH, Offenburg, Germany). A standard curve was obtained by placing a serial dilution of the cell suspension in the bottom wells. The results were expressed as chemotaxis index (CI = number of cells migrated towards chemoattractant/ number of cells migrated towards medium). cAMP/Ca 2+ -dependent transcription factor array -pBP, SIRT6 WT, pRS and sh2 SIRT6 BxPC-3 cells (8 x 10 6 cells/dish) were seeded onto 100 mm cell culture dishes and allowed to adhere for 24 h. Cells were incubated with PMA (25 ng/ml) for 45 min in complete RPMI1640 medium. Cells were then lysed and nuclear extracts were prepared with the nuclear extraction kit, according to the manufacturer's instructions (Panomics, Vignate, Milan, Italy). Nuclear extracts were analyzed with the cAMP/Ca 2+ Protein/DNA Array (Panomics). Membranes were treated according to instructions; positive spot detection and densitometry were performed using a ChemiDoc System (Bio-Rad, Segrate, Milan, Italy). Mice -All mouse experiments were performed in accordance with the relevant laws and institutional guidelines for animal care and use following approval by the Institutional Animal Care and Use Committee of the Advanced Biotechnology Center (ABC, Genoa, Italy). For the generation of bone marrow derived dendritic cells (BMDCs), bone marrow was recovered from femurs and tibiae of 2-weeks old wild type (WT) and Sirt6KO mice (27) . Reporter assays for NF-κB activity -Cells were plated in 24-well plates, allowed to adhere overnight and subsequently transfected with 0.5 µg NF-κB-Luc and 1 ng SV40-Renilla vectors. 24 hours after transfection, cells were stimulated with 25 ng/ml PMA. Luciferase activity was measured 39 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega Italia S.r.l., Milan, Italy) according to the manufacturer's instructions. The luciferase signal was normalized to the renilla signal and, subsequently, to the values obtained in unstimulated control cells, and expressed as Relative Luciferase Units (RLU).
Purification and analysis of bone marrow derived dendritic cells (BMDCs) -We generated
BMDCs by culturing bone marrow precursors in granulocyte macrophage-colony stimulating factor (GM-CSF) (Miltenyi Biotec, Bologna, Italy) supplemented media as previously described (34) . Dendritic cell purity was analyzed by flow cytometry (FACSCanto, BD Bioscience) using anti-mouse APC-conjugated CD11c antibody (Biolegend, CA, USA). Isolated BMDCs were CD11c + (> 70%). At day 7 BMDCs (10 6 cells/ml) were stimulated with 1 µg/ml CpG (TIB MOLBIOL, Genoa, Italy) for 2, 4, 6, or 24 h. Thereafter, cells were harvested and total RNA was extracted for qPCR analysis. Gene expression analysis from microarray dataset -Datasets GSE15471, GSE16515 (Affymetrix U133 Plus 2.0 array) (35, 36) , and GSE1542 (Affymetrix U133 B array) (37) were downloaded from the Gene Expression Omnibus Repository (GEO, http://www.ncbi.nlm.nih.gov/geo) and imported into Partek Genomics Suite 6.6 (Partek Inc., St Louis MO, USA). Probesets were annotated according to human genome assembly GRCh37.p8. In case of multiple probesets for SIRT6 (Affymetrix U133 Plus 2.0), only the one exhibiting the widest variance was retained. Before merging data, expression values from normal and cancer samples in each dataset were transformed into z-scores, as follows: (SIRT6/1 value -SIRT6/1 average )/SIRT6/1 standard deviation . Z-scores were then loaded into R version 2.14.1 (Copyright 2011 The R Foundation for Statistical Computing) for further analysis and graph generation. The Levene's test was used to test the equality of variance in cancer vs. normal samples, whereas comparison of means was performed using the Welch's test. All tests were two-tailed. Statistical analysis -All data are represented as mean ± SD of at least three independent duplicate experiments. Statistics were performed with GraphPad Prism software version 5 (GraphPad Software) using one-way ANOVA for multiple group comparison or unpaired t test for two group comparison. P-values below 0.05 were considered significant.
RESULTS

SIRT6, but not SIRT1, promotes the expression of inflammatory cytokines in pancreatic cancer
cells -We and others have previously reported a role for SIRT6 in the regulation of TNF, IFN-γ, and IL8 expression in immune cells (11, 12, 15) . In order to investigate a possible role of SIRT6 in the production of pro-inflammatory cytokines by PDAC cells, we engineered the PDAC cell line BxPC-3 to stably overexpress wild-type (WT) SIRT6 or the empty vector pBABEpuro (pBP) (Fig. 1 A) (38) . In addition, we generated BxPC-3 cells where SIRT6 expression was reduced with a validated RNA-interference construct (sh2 SIRT6) (Fig. 1 B) (25) . We stimulated these cell lines with phorbol 12-myristate 13-acetate (PMA) and monitored the induction of a panel of 93 immune genes using commercially available low-density arrays. With this approach, we were able to identify a pool of genes whose expression was likely to be promoted by SIRT6 since it was higher in SIRT6-overexpressing cells and lower in SIRT6-silenced cells as compared to the respective controls (Fig. 1 C) . Among these genes were those encoding for the cytokines TNF, IL1α, IL6, IL8, and Colony Stimulating Factor 1 (CSF1), but also for the co-stimulation molecule CD40. In the subsequent experiments, we decided to focus on the role of SIRT6 in TNF and IL8 production by PDAC cells since these were influenced by SIRT6 level modifications to the highest extent. In addition, TNF and IL8 are frequently highly expressed by primary PDACs and are thought to play a role in PDAC pathogenesis and clinical manifestations (4, (39) (40) (41) (42) (43) . In follow-up experiments, we confirmed that SIRT6 overexpression increased TNF and IL8 production at the mRNA and at the protein level ( Fig. 2 B and C) . In agreement with these findings, SIRT6 silencing blunted TNF and IL8 production at both messenger and protein level (Fig. 3) . To assess whether SIRT6 enzymatic activity was required for its capacity to promote TNF and IL8 expression, we engineered BxPC-3 cells with a catalytically inactive SIRT6 isoform (SIRT6 H133Y) (24) and monitored TNF and IL8 mRNA and protein expression in basal conditions and in response to PMA, which was previously shown to potently stimulate the synthesis of these two cytokines (44, 45) . Overexpression of WT SIRT6, but not of SIRT6 H133Y, reduced the acetylation level of Histone H3 lysine 9 (H3K9), a substrate of SIRT6 deacetylase activity (Fig. 2 A) . As compared to SIRT6 H133Y, WT SIRT6 increased TNF and IL8 expression to a much greater extent both in unstimulated and in PMA-stimulated cells, thus showing that SIRT6 enzymatic activity is crucial for its capacity to promote cytokine production ( Fig. 2 B, C) . The increased levels of TNF and IL8 mRNA that we detected in SIRT6-overexpressing cells could reflect increased gene expression or enhanced mRNA stability. To rule out one of these possibilities, we treated control and SIRT6-overexpressing BXPC-3 cells with actinomycin D to inhibit transcription. In both cell types, IL8 and TNF mRNA induction by PMA was virtually abolished by this inhibitor (data not shown), suggesting that enhanced gene transcription was responsible for the increased levels of cytokines produced in response to SIRT6 activity. In subsequent experiments, we sought to confirm SIRT6 role in cytokine expression in a different mammalian model. To this end, we generated BMDCs from wild type and Sirt6KO mice, stimulated them with CpG, and monitored the expression of Tnf and of Cxcl1 and Cxcl2 (mouse functional homologs of human IL8). Consistent with what observed in human cells, Sirt6 deficiency was associated with impaired Tnf, Cxcl1 and Cxcl2 mRNA induction upon stimulation (Fig. 4) . Finally, we aimed at assessing whether SIRT6 propensity to enhance cytokine expression would also extend to other sirtuins. To this aim, WT and catalytically inactive (H363Y) SIRT1 were expressed in BXPC-3 cells (Fig. 5 A) . Cells overexpressing WT SIRT1, but not SIRT1 H363Y showed reduced TNF mRNA levels in baseline conditions and in response to PMA stimulation (Fig. 5 B) . In line with these findings, SIRT1 silencing, as obtained with specific siRNAs, resulted in increased TNF mRNA induction in response to PMA (Fig. 5 C,  D) . These findings are consistent with previous evidence of an anti-inflammatory function for SIRT1 (46, 47) and indicate that SIRT6 proinflammatory activity is not shared by all sirtuins.
Sirtuin inhibition and the NAD + -lowering drug FK866 reduce cytokine secretion in PDAC cells -Since SIRT6 relies on NAD
+ availability for its enzymatic activity, we assessed whether depleting intracellular NAD + would affect IL8 and TNF synthesis in BxPC-3 cells. To this end, FK866 was used to block Nampt, the enzyme that, together with NMNAT, is responsible for NAD + synthesis from nicotinamide (48) . In addition, the effect of the pan-sirtuin inhibitor sirtinol on cytokine secretion was evaluated. Intracellular NAD + content was strongly reduced in BxPC-3 cells after a 48 h incubation with FK866, while addition of nicotinic acid (Na) rescued NAD + depletion through an alternative biosynthesis pathway (49) (Fig. 6 A) . BxPC-3 cell treatment with FK866 significantly reduced PMA-induced IL8 and TNF expression and secretion (Fig. 6 B, C) . However, concomitant Na administration restored cytokine expression at control levels ( Fig. 6 B, C) . Treatment with sirtinol also lowered IL8 and TNF synthesis, both at the mRNA and protein level (Fig. 6 B (Fig. 7 A) (Fig. 7 B) . In addition, PMA increased [Ca 2+ ] i in pRS cells, but not in cells where SIRT6 had been knocked down by RNAi (Fig. 7 C) . These results indicated that SIRT6, through its enzymatic activity, enhances Ca 2+ responses in PDAC cells, and thus suggested a suitable mechanism for the capability of this sirtuin member to promote cytokine secretion. In addition to favoring the expression of inflammatory cytokines, Ca 2+ is a critical regulator of cell migration in different cell types, including cancer cells (50) . To further explore if the increased Ca 2+ responses observed in PMAstimulated SIRT6 over-expressing cells would also confer increased propensity to migrate, we performed chemotaxis assays using PMA or IL8 as chemoattractants. Indeed, BxPC-3 cells expressing WT SIRT6 showed increased capacity to migrate towards these stimuli as compared to vector and SIRT6 H133Y cells (Fig. 7 D) . Vice versa, SIRT6 silencing completely abrogated BxPC-3 cell migration towards PMA and IL8 (Fig. 7 E) . SIRT6 regulates the intracellular levels of the second messenger ADPr -By virtue of its deacetylase activity, sirtuins convert NAD + to nicotinamide and OAADPr (51) (52) (53) . OAADPr, either as such or upon conversion to ADPr, is a ligand of the cation channel TRPM2 (54) (55) (56) , which, in turn, was shown to promote Ca 2+ influx and chemokine production in human and murine leukocytes (20) . Thus, we hypothesized that SIRT6 enzymatic activity could promote Ca 2+ responses and cytokine secretion by increasing the intracellular concentration of ADPr. By using an HPLC-based method, we measured the intracellular concentration of ADPr in BxPC-3 cells engineered to express different amounts of SIRT6 or SIRT6 H133Y. WT SIRT6-overexpressing BxPC-3 cells contained higher amounts of ADPr as compared to the vector control cells and to the SIRT6 H133Y expressing cells (Fig. 8 A) . In line with these findings, SIRT6-silenced cells contained lower ADPr concentrations than their control cells (Fig. 8 B) . Therefore, these experiments confirmed that SIRT6 regulates the intracellular ADPr concentration through its catalytic activity.
To define the role of the ADPr-gated Ca 2+ channel TRPM2 in IL8 and TNF synthesis by PDAC cells, we knocked down its expression with siRNAs in BxPC-3 cells that expressed either pBP or WT SIRT6 (Fig. 8 C, and data not shown). In both cell types, TRPM2 silencing strongly reduced both IL8 and TNF induction by PMA (Fig. 8 D, and data not shown), thus confirming a key role for this cation channel in promoting cytokine expression. TNF and IL8 expression in response to SIRT6 partially relies on NFAT but is independent from NF-κB -In order to identify transcription factors that could be involved in mediating cytokine gene expression in response to SIRT6-derived Ca 2+ -mobilizing metabolites, we investigated the nuclear translocation of 20 cAMP/Ca 2+ -dependent transcription factors using a transcription factor array. As shown in Fig. 9 A, GATA4 and NFAT levels were significantly increased in nuclear extracts from SIRT6 WT cells (2.14 ± 0.30 and 2.24 ± 0.26 fold, respectively), as compared to pBP cells. Accordingly, GATA4 and NFAT levels were slightly decreased in cells with silenced SIRT6 expression (0.65 ± 0.07 and 0.81 ± 0.07 fold, respectively), as compared to pRS cells. In addition, the transcription factor AP-1 was increased in nuclear extracts from SIRT6 WT cells compared to control cells (2.55 ± 0.16 fold) but its levels did not differ between sh2 SIRT6 cells and their control. Conversely, the transcription factor SP1 showed a reduced nuclear expression in sh2 SIRT6 cells (0.43 ± 0.13 fold), but was not increased in SIRT6 WT cells. In subsequent experiments, we focused on NFAT and GATA4 since their nuclear translocation appeared to be consistently regulated by SIRT6 and since both have previously been shown to be dependent on Ca 2+ signaling for their activation (57, 58) . To determine a potential relevance of the calcineurin-NFAT pathway in the control of cytokine expression downstream of SIRT6 we made use of the calcineurin inhibitor cyclosporin A (57). Indeed, this inhibitor reduced TNF and IL8 induction in response to PMA in SIRT6-overexpressing as well as in pBP (not shown) BxPC-3 cells (Fig. 9 B) . To assess whether GATA4 would also play a role in SIRT6-induced cytokine production, we silenced this transcription factor with siRNAs (Fig. 9 C) . However, GATA4 silencing failed to blunt TNF and IL8 induction in SIRT6-overexpressing as well as in pBP (not shown) BxPC-3 (Fig. 9 D) . The transcription factor NF-κB is also well known for promoting the expression of proinflammatory cytokines and SIRT6 was reported to reduce its activity by deacetylating histone H3 at NF-κB promoter sites (59) . In view of this evidence, we sought to assess the role of NF-κB in cytokine expression in BxPC-3 PDAC cells and to determine the impact of SIRT6 on the activity of this transcription factor. In our hands, the IKK inhibitor BAY 11-7082 reduced NF-κB activity, as detected with a NF-κB luciferase reporter assay, and blunted TNF and IL8 induction in response to PMA (Fig. 10 A, B) , thus confirming a role for NF-κB signaling in the expression of these cytokines. In transcription factor arrays, NF-κB p65 levels were slightly increased in the nuclei of SIRT6 WT cells as compared to pBP cells (1.30 ± 0.03 fold), while nuclei from BxPC-3 cells with silenced SIRT6 exhibited reduced NF-κB p65 amounts as compared to pRS cells (0.44 ± 0.18 fold). However, interestingly, these changes failed to translate into consistent modifications in NF-κB transcriptional activity since this was affected neither by SIRT6 overexpression nor by its silencing (Fig. 10 C, D) . Therefore, SIRT6 seems not to affect global NF-κB-dependent transcription in BxPC-3 cells and SIRT6-induced cytokine secretion appears to occur independently from NF-κB activation. SIRT6 expression in PDACs -Given SIRT6 role in cytokine secretion and in the promotion of cell motility in PDAC cells, we assessed its expression in primary pancreatic cancers as compared to healthy pancreatic tissue. To this end, we analyzed three independent, wellannotated gene expression microarray datasets (35) (36) (37) . In order to compare the available data, gene expression values were transformed into zscores (see Methods for details). SIRT6 values from 179 samples were therefore pooled together, including 99 cancers and 80 healthy tissues. Overall, normal tissues exhibited greater variability in SIRT6 expression compared to pancreatic cancers (p-value < 0.01), possibly reflecting some heterogeneity in specimen isolation from healthy pancreas. SIRT6 expression was significantly lower in pancreatic cancer samples than in their normal counterparts (p-value < 0.0001). (Fig. 11 A) . Conversely, no difference in SIRT1 expression between healthy pancreatic tissue and pancreatic cancers was detected using the same approach (Fig. 11 B) . In addition, we determined by qPCR SIRT6 mRNA levels in several PDAC cell lines and compared them to those in non-tumorigenic HPNE cells (Human Pancreatic Nestin Expressing cells) (60) . Here, we found that eight out of twelve PDAC cell lines had higher SIRT6 levels as compared to HPNE cells, while only one cell line (E3LZ10.7) had lower SIRT6 expression (Fig. 11 C) .
DISCUSSION
In our study, we show that SIRT6 promotes the expression of inflammatory cytokines by PDAC cells and enhances their migratory capacity by a mechanism that includes ADPr production and ADPr-triggered Ca 2+ responses (via TRPM2). Together with TNF, we found that several other cytokines are regulated by SIRT6 activity, including IL-1α, IL-6, IL8, and CSF1. Among these, IL8 is frequently detected in high concentrations in the plasma of PDAC patients and plays a key role in the pathogenesis of this neoplasia by promoting local inflammation, by enhancing angiogenesis, and by supporting PDAC growth via autocrine stimulation (40) (41) (42) (43) . In addition, IL8 has recently been shown to promote Epithelial mesenchymal transition (EMT) (4) . With respect to the mechanism by which SIRT6 regulates cytokine synthesis, we found that this effect relies, at least in part, on SIRT6 capacity to modulate intracellular ADPr levels and, consequently, to promote Ca 2+ responses inside the cell. Particularly, TRPM2 gating by SIRT6-derived ADPr appears to be key for this outcome. Previous studies focusing on SIRT2 and SIRT3 had established a link between sirtuin-derived OAADPr and TRPM2-dependent Ca 2+ signaling (54) . However, SIRT6 activity as a deacetylase had recently been questioned and its capacity to synthesize OAADPr was found to be very slow as compared to other active sirtuins (26) . In our hands, modulating intracellular SIRT6 levels affected H3K9 acetylation levels and, importantly, determined significant changes in intracellular ADPr concentration. These effects appeared to be related to SIRT6 enzymatic activity as a catalytically inactive isoform (SIRT6 H133Y) failed to recreate them. As a downstream effector of SIRT6-promoted Ca 2+ responses we identified the transcription factor NFAT, as suggested by the findings that NFAT representation in the nucleus is increased by SIRT6 overexpression and reduced by SIRT6 silencing, and that pharmacological inhibition of calcineurin [the phosphatase that promotes NFAT nuclear translocation in response to Ca 2+ (57) ], reduces TNF and IL8 induction in SIRT6-overexpressing pancreatic cancer cells. With respect to the impact of SIRT6 on NF-κB signaling, we found that, in BxPC-3 cells, SIRT6 promoted NF-κB nuclear relocalization (in particular, nuclear NF-κB p65 amounts were strongly reduced in SIRT6-silenced cells). However, despite this effect, modulating SIRT6 levels did not have a major influence on NF-κB-dependent transcription. It could be hypothesized that, while SIRT6-mediated Ca 2+ responses favor NF-κB translocation to the nucleus (61), here, its activity would be held back by SIRT6-dependent histone deacetylation at NF-κB target gene promoters (59) . Thus, the lack of efficacy of SIRT6 at modulating NF-κB activity in this system could be explained by the coexistence of opposing and mutually neutralizing forms of regulation. Overall, our findings i) indicate that SIRT6 deacetylase activity in vivo is relevant, ii) identify SIRT6 as an important source of Ca 2+ mobilizing second messengers, and iii) place this sirtuin, together with SIRT2 and SIRT3 (54), upstream of TRPM2 in a signaling pathway that culminates in Ca 2+ fluxes and consequent gene expression regulation (Fig. 12) . Interestingly, as opposite to SIRT6, SIRT1 appears to reduce, instead of increasing, TNF production by pancreatic cancer cells. These findings are consistent with previous literature indicating that SIRT1 downmodulates immune cell reactivity by deacetylating c-Jun and consequently yielding an inactive AP-1 factor, and by reducing NF-κB activity (23, 46) . Finally, it should be noticed that, although to a much lesser extent as compared to WT SIRT6, also SIRT6 H133Y promoted TNF and IL8 production in BxPC-3 cells. This effect seems unrelated to ADPr level modifications since ADPr amounts and Ca 2+ responses in SIRT6 H133Y cells were comparable to those observed in control cells. Therefore, SIRT6 may also enhance cytokine secretion via mechanisms that are unrelated to its enzymatic activity and to ADPr synthesis. The fact that in our cell models SIRT6 promoted cytokine production by enhancing gene expression is in partial contrast with a previous study showing that NAD + availability and SIRT6 activity do not enhance Tnf gene expression, but rather the efficiency with which Tnf mRNA is translated (11) . A possible explanation for this discrepancy is that Van Gool and colleagues, as opposite to us, drew their conclusions largely based on data obtained with chemical inhibitors, such as nicotinamide, sirtinol, cambinol and FK866, which can affect numerous cellular processes. Moreover, a different cell model was used by these authors (mouse RAW 264.7 macrophages).
Nonetheless, although highlighting a clear role for SIRT6 in the regulation of cytokine mRNA, our experiments do not exclude that a mechanism for cytokine synthesis regulation by SIRT6 such as that proposed by Van Gool et al. (cytokine mRNA translation regulation) also takes place and contributes to the phenotypes that we observed. In line with its capacity to enhance Ca 2+ responses inside the cell, we found that SIRT6 also promoted cell migration, which is another cellular function that strongly depends on Ca 2+ entry (50) . Thus, these results link SIRT6 to another key function of cancer cells that is involved in metastatic dissemination and local invasion (2) . Interestingly, despite the fact that SIRT6 clearly promotes a pro-inflammatory phenotype in PDAC cells, its levels in pancreatic cancer appear to be lower than those in normal pancreatic tissue (at least at the mRNA level). This counterintuitive finding could be explained by the fact that SIRT6, in addition to its role in genome stability and inflammation, is involved in glucose metabolism (11, 27, 62) . Namely, SIRT6 deficiency results in increased glucose uptake by the cell and in increased glycolysis (62) . Thus, it is conceivable that cancer cells could use low SIRT6 levels to support their glycolytic metabolism (Warburg effect). It is however noteworthy that, as opposite to what observed in primary tumors, the majority of PDAC cell lines examined were found to have increased SIRT6 levels as compared to the nontumorigenic pancreatic epithelial cells HPNE. Although this observation refers to cell lines and could be explained for instance by forms of adaptations to defined culture conditions, it is appealing to speculate that SIRT6 upregulation could actually occur at certain stages of pancreatic carcinogenesis and possibly be associated with advanced or highly aggressive forms of cancer such as those which cancer cell lines are typically generated from. Overall, our study shows that SIRT6 enzymatic activity is linked to the production of Ca 2+ -mobilizing nucleotides, such as ADPr. This results in increased Ca 2+ signaling, inflammatory gene expression, and cell motility. Future studies will have to address the real benefit of SIRT6 inhibition in cancer, possibly addressing the issue of SIRT6 contribution to different stages of cancer progression. Thereafter, cells were stimulated with 25 ng/ml PMA. 48h later cells were used for RNA isolation and TNF and IL8 levels were detected by qPCR. (C, D) , SIRT6-overexpressing BxPC-3 cells were transfected with or without scrambled siRNAs or with anti-GATA4 siRNAs. 24h later, cells were used for RNA isolation and GATA4 mRNA was quantified by qPCR (C). Alternatively, cells were stimulated with PMA for additional 48h before RNA was isolated and TNF and IL8 levels were determined by qPCR (D). Data are shown as mean ± SD (n=3). P-values were calculated vs. unstimulated control cells (B CTR, C,D siSCR) using unpaired t test: ***p<0.0005, *p<0.05, ns p>0.05. FIGURE 10. SIRT6 does not affect NF-κB transcriptional activity in BxPC-3 cells. A, NF-κB-dependent transcription was measured with an NF-κB reporter gene system in BxPC-3 cells stimulated or not with 25 ng/ml PMA for 15 h. Before PMA addition, cells were pre-incubated for 1h with or without 20 μM BAY 11-7082. One representative experiment out of two is shown. B, BxPC-3 cells were pre-incubated for 1h with or without 20 μM BAY 11-7082. Subsequently, cells were stimulated with or without 25 ng/ml PMA for 2 h. Thereafter, cells were used for RNA extraction and IL8 and TNF mRNA levels were quantified by qPCR. Data are expressed as mean ± SD (n=3). Pvalues were calculated using unpaired t test: ***p<0.0005 C, D, NF-κB-dependent transcription was measured with an NF-κB reporter gene system in pBP, SIRT6 WT (C), pRS, and sh2 SIRT6 (D) BxPC-3 cells stimulated or not with 25 ng/ml PMA for 15 h. Data are expressed as mean ± SD (n=3). P-values were calculated using unpaired t test: ns p>0.05. 
